Heparin Market| Regional Growth Forecast 2021-2027

Heparin Market| Regional Growth Forecast 2021-2027

The heparin market is slated to witness considerable growth over the coming years owing to the rising prevalence of chronic illness across the globe. Increasing demand for anticoagulants products is also anticipated to accelerate the overall market share. Furthermore, favorable initiatives undertaken by organizations like the CDC and the NIH (National Institutes of Health) to increase awareness levels through different programs is likely to boost the market outlook in the coming years.

As per a new study, heparin, which is known to be a common blood-thinning medicine, is in fact, being increasingly utilized to treat COVID-19 patients. There is strong evidence that heparin helps in preventing some of the damaging effects of the COVID-19 and even halting the virus from attaching to cells in the body. In July 2020, Rensselaer Polytechnic Institute researchers discovered that heparin was equally as effective at blocking the coronavirus infection in cells for the treatment of COVID-19 than remdesivir. This has greatly catapulted the market value of heparin, which would lucratively drive industry share.

Request for a sample copy of this report @ https://www.decresearch.com/request-sample/detail/4837  

As per a Global Market Insights, Inc., report, heparin market is slated to surpass a $6.6 billion valuation by 2026.    

In terms of application, the heparin market is categorized into atrial fibrillation/flutter, venous thromboembolism, coronary artery disease, and others. Among these, the coronary artery disease segment will witness substantial growth over the coming years. In 2019, the segment  accounted for approximately $1.0 billion. This anticipated growth is ascribed to the rising prevalence of coronary artery disease across developing nations. Arterial thrombosis is usually caused when atherosclerosis damages the artery. This further leads to myocardial infraction as well as coronary artery disease, thereby augmenting the demand of heparin.

On the geographical front, Asia Pacific heparin industry is anticipated to witness the fastest growth in the forthcoming years. This can be ascribed to the presence of a large patient pool across highly populated countries, like China and India, who are prone to high number of chronic disorders. As per reports by the APAC Thrombosis Advisory Board, in 2017, VTE (venous thromboembolism) was considered among the most common disorders in people of Asian descent. In fact, the VTE incidence rate was nearly 100 per 100,000 population per annum. This growing prevalence of chronic disorders is likely to augment the regional demand. Additionally, high presence of mass local manufacturers across Southeast Asia would also propel the regional growth.

Request for customization @ https://www.decresearch.com/roc/4837

With the increasing number of chronic diseases, many companies are coming up with new, innovative solutions in the medical domain to strengthen their position in the industry. Citing an instance, in November 2019, Fresenius Kabi, a global healthcare company, reportedly announced the launch of its new heparin sodium injection, with USP Simplist® Prefilled syringe in 5,000 USP units/0.5 mL presentation. The new syringes would be available in the United States and the drug’s active pharmaceutical ingredient would be sourced from Europe. With the combination of a small-volume presentation of Heparin and other ready-to-administer prefilled syringes, the new product would support safe practices for heparin medication.

Laboratorios Farmaceuticos Rovi SA, Hepalink group, Amphastar Pharmaceutical, Leo Pharma, Pfizer, and Sanofi among many others are some of the key players operating in the heparin market.

Partial Chapter of the Table of Content

Chapter 2   Executive Summary

2.1    Heparin industry 360° synopsis, 2015-2026

2.1.1    Business trends

2.1.2    Product trends

2.1.3    Source trends

2.1.4    Application trends

2.1.5    Distribution channel trends

2.1.6    Regional trends

Chapter 3   Heparin Industry Insights

3.1    Industry segmentation

3.2    Industry landscape, 2015 - 2026

3.3    Industry impact forces

3.3.1    Growth drivers

3.3.1.1    Growing prevalence of chronic diseases

3.3.1.2    High demand for anticoagulants products

3.3.1.3    Rising geriatric population across the globe

3.3.2    Industry pitfalls & challenges

3.3.2.1    High risk of side effects

3.3.2.2    High dependency on porcine

3.4    Growth potential analysis

3.4.1    By product

3.4.2    By source

3.4.3    By application

3.4.4    By distribution channel

3.5    COVID-19 impact analysis

3.6    Porter’s analysis

3.7    Competitive landscape

Browse complete Table of Contents (ToC) of this research report @ https://www.decresearch.com/toc/detail/heparin-market